



NORTHAMPTONSHIRE PRESCRIBING ADVISORY GROUP
(Advising Medical, Pharmacy Practitioners and Non-Medical Prescribers
on prescribing across the county)

Summary of Recommendations from meeting on Weds 20th April 2016

- **Catephen® (Green tea leaf extract)**
Catephen is licensed for the cutaneous treatment of external genital and perianal warts in immunocompetent patients from the age of 18 years. Following advice from a local sexual health clinician **NPAG categorised Catephen as double red (prior approval)**
- **Guanfacine (Intuniv®)**
Guanfacine is a new non-stimulant drug licensed for treatment of ADHD in children. NPAG proposed that it should initially be considered at the NHfT Formulary Committee in July and that it could then be brought back to NPAG in August.
In the interim **NPAG categorised guanfacine as grey.**
- **Blepharitis Eye Bag**
NPAG agreed that blepharitis should be self-managed and that this was consistent with previous decisions regarding treatments for blepharitis.
NPAG categorised Blepharitis Eye Bags as double red (IFR).
- **Cholib® (fenofibrate and simvastatin)**
NPAG discussed that this combination of drugs would NOT usually be recommended, but if it was required the drugs could be prescribed separately. **NPAG categorised Cholib as double red (IFR).**
- **Brivaracetam (Briviact®)**
This is a new product licensed as adjunctive therapy for partial onset seizures with or without secondary generalisation in patients from 16 years of age. Brivaracetam works in a similar way to levetiracetam however there are no comparative trials. The place of Brivaracetam in treatment management is currently unclear relative to other antiepileptics recommended by NICE. **NPAG categorised as double red IFR.**
- **Prucalopride**
Prucalopride was originally categorised as amber 2 with prior approval to ensure efficacy of treatment prior to transfer of prescribing to GP. Local consultants have now requested that the prior approval element is removed.
NPAG agreed to re-categorise as amber 2 and shared care to be developed.
- **Shared Care**
The following shared care guidelines/letters were agreed and will shortly be available on Pathfinder:
 - Rifaxamin
 - Toujeo
 - Ciclosporin ophthalmic emulsion (Ikervis®)
- **Local Guidelines**
The following local guidelines were agreed and will shortly be available on Pathfinder <http://www.pathfinder-rf.northants.nhs.uk/nene/therapeutics/guidelines-dermatology/> :
 - Acne
 - Actinic keratosis
 - Rosacea
- **NICE guidance**
NPAG noted the following NICE guidance
 - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia <http://www.nice.org.uk/guidance/ta385>

Further information or clinical trial data may be obtained from the CCG Prescribing Advisers or Hospital Medicines Information Service.

Information in this bulletin is believed to be true and accurate. The NHS and their employees accept no liability for loss of any nature, to persons, organisations or institutions that may arise as a result of any errors or omissions.